Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pilot Study of Hydroxychloroquine for the Treatment of AIMSS (AIMSS)

16. september 2026 oppdatert av: Tarah J Ballinger, MD, Indiana University

A Phase II Single-Arm Pilot Study of Hydroxychloroquine for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome

The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase Inhibitor Associated Musculoskeletal Syndrome (AIMSS) for patients with breast cancer.

Studieoversikt

Detaljert beskrivelse

Aromatase Inhibitor (AI) therapy is highly effective for post-menopausal, estrogen receptor (ER) positive breast cancer, yet the clinical effectiveness of AI therapy is limited by noncompliance and early treatment discontinuation due to musculoskeletal side effects, which include joint pain, joint stiffness, bone pain, muscle weakness, and myalgias. Methods to improve compliance to AI therapy have the potential to increase survival.

This study will look at hydroxychloroquine (HCQ), a disease-modifying antirheumatic drug (DMARD) with well-established anti-inflammatory and immunomodulatory properties. It is FDA-approved for the treatment of conditions characterized by chronic inflammatory joint pain similar to AIMSS. This single-arm, proof of concept study will look for an improvement in joint pain for patients undergoing standard of care treatment involving AI therapy.

Studietype

Intervensjonell

Registrering (Antatt)

35

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Niraj Shah, MS
  • Telefonnummer: 317-278-3420
  • E-post: shahnir@iu.edu

Studiesteder

    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
        • Hovedetterforsker:
          • Tarah Ballinger, MD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 18 years at the time of informed consent
  2. Ability to provide written informed consent and HIPAA authorization
  3. Diagnosis of DCIS or stage I, II, or III breast cancer
  4. Currently receiving adjuvant aromatase inhibitor therapy (anastrozole, letrozole or exemestane) for ≥ 4 weeks prior to enrollment Note: Concurrent use of ovarian suppression is allowed Note: Concurrent use of CDK4/6 inhibitors is not allowed due to cytopenia risk
  5. New or worsening self-reported musculoskeletal pain that began or significantly worsened after initiation of AI therapy
  6. BPI average pain score of ≥ 4 during screening
  7. ECOG PS 0-2
  8. Adequate organ function:

    1. Absolute neutrophil count ≥1,500/µL
    2. Hemoglobin ≥11.0 g/dL
    3. Platelet count ≥100,000/µL
    4. Serum creatinine ≤1.5× upper limit of normal (ULN) or eGFR ≥60 mL/min/1.73m2
    5. Total bilirubin ≤1.5× ULN (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)
    6. AST and ALT ≤1.5× ULN
  9. Must agree to maintain stable doses of any analgesic medications or other AIMSS related therapies during the study period Note: rescue doses of acetaminophen or ibuprofen allowed on a non-daily basis, unless not new

Exclusion Criteria:

  1. Current or prior use of hydroxychloroquine or chloroquine within 6 months
  2. Known hypersensitivity to hydroxychloroquine, chloroquine, or 4-aminoquinoline compounds
  3. History of retinopathy or retinal vein occlusion issues Note: While there is an association between retinopathy and HCQ use, this occurs rarely and with long term use with higher cumulative doses that used here. Other clinical trials have not required retinal exam (example: CTO-TBCRC04627, approved by IU IRB)
  4. History of congestive heart failure (any NYHA class)
  5. QTc prolongation (>450 msec) at screening or history of significant arrhythmias requiring treatment
  6. Moderate to severe renal impairment (eGFR <60 mL/min/1.73m2)
  7. Use of a prohibited concomitant medication (refer to Section 6.3.2) that cannot be discontinued or changed to an alternate therapy
  8. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency
  9. History of porphyria
  10. History of psoriasis
  11. History of antiepileptic medications
  12. Known history of inflammatory arthritis (example: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) or connective tissue disease (example: systemic lupus erythematosus, scleroderma, polymyositis)
  13. Recent initiation or dose change (within 4 weeks) of medications for pain management (NSAIDs, duloxetine, gabapentin, pregabalin, opioids) Note: Patients on stable doses for >4 weeks are eligible
  14. Patients currently receiving or planned to receive high dose systemic treatment with corticosteroids defined as: cortisone >50mg; hydrocortisone >40mg, prednisone >10mg, methylprednisolone >8mg or dexamethasone >1.5mg; or another immunosuppressive agent Note: Topical or inhaled corticosteroids are allowed
  15. Other active malignancy other than breast cancer requiring systemic therapy
  16. Pregnant or lactating
  17. Co-enrollment in another clinical trial Note: Patients may co-enroll in other clinical trial(s) if the trial(s) does not interfere with the objectives of this trial
  18. Significant psychiatric illness, in the opinion of the investigator, that would limit compliance with study requirements
  19. Any active suicidality or history of active suicidal ideation/behavior/attempt within 1 year prior to screening
  20. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Hydroxychloroquine sulfate
Hydroxychloroquine sulfate, 400 mg orally once daily
Drug: Hydroxychloroquine sulfate Dose: 400 mg orally once daily Duration: 12 weeks

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To evaluate the efficacy of hydroxychloroquine
Tidsramme: Day 1 and Week 12
To evaluate the efficacy of hydroxychloroquine 400 mg daily in reducing joint pain associated with AIMSS as measured by change in Brief Pain Inventory (BPI) Average Pain score (scored from 0-10; a minimally important difference is a 2-point reduction or 30% from baseline).
Day 1 and Week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of patients achieving a clinically meaningful improvement
Tidsramme: Day 1 and Week 12
To assess the proportion of patients achieving a clinically meaningful improvement (≥2-point reduction) in BPI Average Pain score.
Day 1 and Week 12
Changes in BPI Worst Pain and Pain Interference scores
Tidsramme: Day 1 and Week 12
To evaluate changes in BPI Worst Pain and Pain Interference scores (scored from 0-10; a minimally important difference is a 2-point reduction or 30% from baseline).
Day 1 and Week 12
Changes in endocrine therapy related quality of life
Tidsramme: Day 1 and Week 12
To assess changes in endocrine therapy related quality of life by FACT-ES (5 point Likert-type scale).
Day 1 and Week 12
Changes in grip strength
Tidsramme: Day 1 and Week 12
To assess changes in grip strength as an objective measure of function using Jamar hand dynamometers (scale of 0-200lbs).
Day 1 and Week 12
Patient-reported global impression of change
Tidsramme: Week 12
To evaluate patient-reported global impression of change using the Patient Global Impression of Change (PGIC) (scale 0-6, 6 being the worst outcome).
Week 12
Safety of hydroxychloroquine in this patient population
Tidsramme: Day 1, Week 4, Week 12, 30 days post EOT
To assess safety of hydroxychloroquine in this patient population using NCI CTCAE v5.0 (grade 1-5, 5 being the worst outcome).
Day 1, Week 4, Week 12, 30 days post EOT
Tolerability of hydroxychloroquine in this patient population
Tidsramme: Day 1, Week 4, Week 12, 30 days post EOT
To assess tolerability of hydroxychloroquine in this patient population via number of patients who completed treatment.
Day 1, Week 4, Week 12, 30 days post EOT
Adherence to aromatase inhibitor therapy
Tidsramme: Screening, Day 1, and Week 12
To evaluate adherence to aromatase inhibitor therapy during the study period via number of patients who completed treatment based on self-report.
Screening, Day 1, and Week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Tarah Ballinger, MD, IUSCCC

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. september 2026

Primær fullføring (Antatt)

1. desember 2029

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

25. august 2026

Først innsendt som oppfylte QC-kriteriene

16. september 2026

Først lagt ut (Faktiske)

17. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere